NVentures

NVentures is the venture capital arm of NVIDIA, headquartered in Santa Clara, California, and stood up to back companies whose strategic direction depends on AI-native architectures and accelerated computing. The fund operates as a strategic, not financial, investor, and its thesis is closely tied to where NVIDIA sees foundational platform opportunities emerging across industries, with healthcare and life sciences among the most active categories.

The healthcare and life sciences thesis spans AI/ML in healthcare, biotech, and pharma and therapeutics, with deep interest in companies building AI-native platforms for drug discovery, clinical research, and provider workflow. Portfolio companies including Abridge, an ambient clinical documentation platform, and VantAI, an AI-driven drug discovery company, reflect the firm’s appetite for category-defining bets where access to compute, model architectures, and NVIDIA’s broader ecosystem materially advantages the company.

NVentures typically participates at Series A and Series B with check sizes of $5M to $25M, often as part of larger syndicates led by traditional venture firms. The firm’s geographic focus is global, with notable activity in U.S. and European AI-driven life sciences companies. Founders should think of NVentures as a strategic co-investor that brings unique technical and ecosystem advantages rather than a lead-investor relationship, though the fund does take meaningful positions and typically secures information rights or board observer seats commensurate with its check size.

The team combines technology investing experience with deep relationships across NVIDIA’s product, research, and developer relations organizations. Investment decisions are made with input from the broader NVIDIA strategic apparatus, which means diligence processes consider not just financial returns but also alignment with NVIDIA’s platform vision and the potential for portfolio companies to become reference customers and ecosystem partners.

The value proposition for founders is unusually concrete. Portfolio companies gain access to NVIDIA’s GPU clusters at scale, technical engagement with the company’s research and engineering teams, and visibility through NVIDIA’s developer and partner programs. For AI-native life sciences companies in particular, the ability to collaborate technically with NVIDIA on infrastructure, model training, and deployment can be a meaningful accelerant. Reporting expectations are professional and aligned with strategic CVC norms, with quarterly check-ins focused on commercial milestones and ongoing technical collaboration. NVentures will not be the right partner for founders building products that conflict with NVIDIA’s strategic interests or for those who need a traditional lead investor with deep board engagement on commercial and operational matters. But for AI-driven biotech and clinical AI founders who can credibly leverage accelerated computing as a core part of their moat, NVentures represents an unusually valuable strategic partner whose participation in a round signals technical credibility and opens doors across NVIDIA’s expansive ecosystem of academic research labs, pharmaceutical companies, and health systems running on NVIDIA infrastructure.